Nektar sells Cimzia and Mircera royalties for $124m to pay down debt
This article was originally published in Scrip
Executive Summary
Nektar Therapeutics raised $124 million by selling its royalties from UCB Pharma's Cimzia and Roche’s Mircera to Royalty Pharma. It will use the money to pay down part of its outstanding $215 million debt.